UNSPSC 51191542: Clorexolone

This classification denotes a diuretic with the molecular formula C14H17ClN2O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Q2PLT3FS05, chemically known as 6-chloro-2-cyclohexyl-2,3-dihydro-3-oxo-1h-isoindole-5-sulfonamide but generally known as clorexolone, which bears US NIH Compound Identifier 16473. European Medicines Agency schedules Clorexolone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06754MIG.

UNSPSC 51191542 Clorexolone is a Commodity code that captures chemical supply for municipal water and wastewater treatment operations, though recent state and local solicitations show the code tagged to sodium bisulfite and multi-source pharmaceutical procurement. State and local governments buy specialized treatment chemicals and pharmaceutical products under this code for use in public health and environmental infrastructure. Issuing bodies include municipal utilities (water pollution control facilities) and state cooperative purchasing alliances managing pharmaceutical distribution across multiple jurisdictions and member facilities. The scope reflects operational procurement for essential supplies in public water systems and healthcare distribution networks requiring vendor compliance with manufacturing standards, FDA requirements, insurance minimums, and supply-chain security protocols.

The City of Meriden, Connecticut solicited sodium bisulfite (IFB B027-15, due July 29, 2026) for its Water Pollution Control Facility, requiring $1 million to $2 million general liability coverage and performance bonds. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP for generic multi-source pharmaceuticals and OTC products (S1070000015802, due March 26, 2026) serving participating state and local government facilities including Oregon, with pricing evaluation weighted 75 percent on price competitiveness, vendor compliance with cGMP and Drug Supply Chain Security Act certification, and $5 million commercial general liability coverage. Recent activity concentrates in Connecticut and Minnesota, with the pharmaceutical RFP reflecting multi-state cooperative purchasing. The mismatch between the code name (Clorexolone) and actual solicitations (sodium bisulfite, pharmaceuticals) suggests the code may not capture its intended scope accurately in practice.